March 19, 2025
This article highlights how one reason for limited progress in glioblastoma treatment in recent years is the lack of understanding of tumor behavior at the proteomic and spatial levels. Integrated proteogenomic characterization—combining genomics, transcriptomics, and proteomics—has emerged as a promising approach to identify patient-specific molecular signatures. These insights can be used to stratify patients and tailor therapies more precisely. Proteogenomics enables the identification of protein-level changes, such as post-translational modifications (PTMs) and signaling pathway activation, that are not evident through genomics alone. It also helps clarify why some genomic features, like tumor mutational burden, do not consistently predict treatment response in glioblastoma.
Dr. Khasraw is highlighted in the article for his leadership in advancing the use of spatial proteomics—a technology that integrates spatial biology with proteogenomic data to examine how the location and interaction of cells within the tumor influence treatment resistance and disease progression. By leveraging spatial omics tools like LC-MS and CODEX, we contribute to uncovering how spatial organization and cellular interactions within glioblastoma drive adaptive resistance mechanisms. This work emphasizes the need for a multiscale, dynamic view of tumor biology, combining molecular depth with spatial resolution to guide precision oncology, which could significantly accelerate the development of personalized, more effective therapies for glioblastoma patients.
Read the full article here.